Table 3.
Visit 4 (day 15) | Combination (n=305) | 0.1% dexamethasone (n=298) | 1% azithromycin (n=155) | Vehicle (n=149) | All subjects (N=907) |
---|---|---|---|---|---|
n* | 303 | 294 | 155 | 148 | 900 |
Mean change from baseline (standard deviation) | −0.8 (0.66) | −0.7 (0.65) | −0.6 (0.69) | −0.6 (0.66) | −0.7 (0.67) |
Within-group P-value§ | <0.0001 | <0.0001 | <0.0001 | <0.0001 | <0.0001 |
Overall and pairwise P-values§ | |||||
vs dexamethasone | 0.3828 | ||||
vs 1% azithromycin | 0.0025 | 0.0220 | |||
vs vehicle | 0.0240 | 0.1237 | 0.5285 | ||
Overall | 0.0089 |
Notes:
There were seven subjects who were enrolled and received the study drug, but did not have any measurements after baseline; these seven subjects were thus not included in the analyses of changes in clinical signs and symptoms. Last observation carried forward was used for imputation of any missing data.
Within-group P-values are from one-sample t-tests on mean change. Overall and pairwise P-values derived from analysis of variance with main effect of treatment groups. Combination =0.1% dexamethasone and 1% azithromycin.